230 related articles for article (PubMed ID: 35283387)
41. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
Nadeau BA; Fecher LA; Owens SR; Razumilava N
Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774
[TBL] [Abstract][Full Text] [Related]
42. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
Fernandes S; Varlamov EV; McCartney S; Fleseriu M
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
[TBL] [Abstract][Full Text] [Related]
43. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors.
Dolladille C; Ederhy S; Allouche S; Dupas Q; Gervais R; Madelaine J; Sassier M; Plane AF; Comoz F; Cohen AA; Thuny FR; Cautela J; Alexandre J
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31988143
[TBL] [Abstract][Full Text] [Related]
44. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
[TBL] [Abstract][Full Text] [Related]
45. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.
Nigro O; Pinotti G; De Galitiis F; Di Pietro FR; Giusti R; Filetti M; Bersanelli M; Lazzarin A; Bordi P; Catino A; Pizzutilo P; Galetta D; Marchetti P; Botticelli A; Scagnoli S; Russano M; Santini D; Torniai M; Berardi R; Ricciuti B; De Giglio A; Chiari R; Russo A; Adamo V; Tudini M; Silva RR; Bolzacchini E; Giordano M; Di Marino P; De Tursi M; Rijavec E; Ghidini M; Vallini I; Stucci LS; Tucci M; Pala L; Conforti F; Queirolo P; Tanda E; Spagnolo F; Cecchi F; Bracarda S; Macrini S; Santoni M; Battelli N; Fargnoli MC; Porzio G; Tuzi A; Suter MB; Ficorella C; Cortellini A
Eur J Cancer; 2020 Jul; 134():19-28. PubMed ID: 32454395
[TBL] [Abstract][Full Text] [Related]
46. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
Chen CH; Yu HS; Yu S
Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
[TBL] [Abstract][Full Text] [Related]
47. Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors.
Sandigursky S; Mor A
Curr Rheumatol Rep; 2018 Sep; 20(10):65. PubMed ID: 30191417
[TBL] [Abstract][Full Text] [Related]
48. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.
Suarez-Almazor ME; Kim ST; Abdel-Wahab N; Diab A
Arthritis Rheumatol; 2017 Apr; 69(4):687-699. PubMed ID: 28085999
[No Abstract] [Full Text] [Related]
49. Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice.
Parthymos I; Liamis G; Dounousi E; Pentheroudakis G; Mauri D; Zarkavelis G; Florentin M
Crit Rev Oncol Hematol; 2020 Jul; 151():102979. PubMed ID: 32480349
[TBL] [Abstract][Full Text] [Related]
50. Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency.
Katakura Y; Kimura T; Kusano T; Tatsumi F; Iwamoto Y; Sanada J; Fushimi Y; Shimoda M; Kohara K; Nakanishi S; Kaku K; Mune T; Kaneto H
Front Endocrinol (Lausanne); 2021; 12():722586. PubMed ID: 34712202
[TBL] [Abstract][Full Text] [Related]
51. Cardiac Toxicity of Immune Checkpoint Inhibitors: Cardio-Oncology Meets Immunology.
Varricchi G; Galdiero MR; Tocchetti CG
Circulation; 2017 Nov; 136(21):1989-1992. PubMed ID: 29158212
[No Abstract] [Full Text] [Related]
52. Management of immune-related adverse events resulting from immune checkpoint blockade.
Baroudjian B; Arangalage D; Cuzzubbo S; Hervier B; Lebbé C; Lorillon G; Tazi A; Zalcman G; Bouattour M; Lioté F; Gautier JF; Brosseau S; Lourenco N; Delyon J;
Expert Rev Anticancer Ther; 2019 Mar; 19(3):209-222. PubMed ID: 30572735
[TBL] [Abstract][Full Text] [Related]
53. Adrenal Insufficiency: Immune Checkpoint Inhibitors and Immune-Related Adverse Event Management.
Hobbs KB; Yackzan S
Clin J Oncol Nurs; 2020 Jun; 24(3):240-243. PubMed ID: 32441673
[TBL] [Abstract][Full Text] [Related]
54. TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis.
Liu X; Wu W; Fang L; Liu Y; Chen W
Front Immunol; 2022; 13():922782. PubMed ID: 35844550
[TBL] [Abstract][Full Text] [Related]
55. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
Zhao JJ; Wen XZ; Ding Y; Li DD; Zhu BY; Li JJ; Weng DS; Zhang X; Zhang XS
Aging (Albany NY); 2020 Jun; 12(11):10663-10675. PubMed ID: 32516130
[TBL] [Abstract][Full Text] [Related]
56. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
[TBL] [Abstract][Full Text] [Related]
57. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer.
Sebastiani GD; Scirocco C; Galeazzi M
Autoimmun Rev; 2019 Aug; 18(8):805-813. PubMed ID: 31176871
[TBL] [Abstract][Full Text] [Related]
58. Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies.
Rogado J; Romero-Laorden N; Sanchez-Torres JM; Ramos-Levi AM; Pacheco-Barcia V; Ballesteros AI; Arranz R; Lorenzo A; Gullon P; Garrido A; Serra López-Matencio JM; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondejar R; Colomer R
Oncoimmunology; 2020; 9(1):1751548. PubMed ID: 32363123
[TBL] [Abstract][Full Text] [Related]
59. Immune-related cutaneous adverse events: A new opportunity for allergists and clinical immunologists.
Leung DYM
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):607. PubMed ID: 34049668
[No Abstract] [Full Text] [Related]
60. Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists.
Kim ST; Suarez-Almazor ME
Expert Rev Clin Immunol; 2019 Mar; 15(3):211-213. PubMed ID: 30589372
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]